Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 5/20 | 0.36 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.35 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | GSK3B | P49841 | 5/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19714391 | 0.93 | CBLB (0.36) | CBLBIRAK4HPGDSABL1NAMPT | |
| SCHEMBL19714392 | 0.93 | CBLB (0.36) | CBLBIRAK4HPGDSABL1NAMPT | |
| SCHEMBL19714394 | 0.93 | CBLB (0.36) | CBLBIRAK4HPGDSABL1NAMPT | |
| SCHEMBL19736471 | 0.92 | ACACB (0.37) | BRD4PLK1MAPTGSK3BPIK3C3 | |
| SCHEMBL19713967 | 0.90 | NAMPT (0.38) | CBLBIRAK4HPGDSABL1NAMPT | |
| SCHEMBL19713968 | 0.90 | NAMPT (0.38) | CBLBIRAK4HPGDSABL1NAMPT | |
| SCHEMBL19736506 | 0.90 | FDPS (0.40) | MAPTGSK3BACACB | |
| SCHEMBL19736179 | 0.86 | HRH3 (0.37) | MAPTGSK3BACACB | |
| SCHEMBL22239575 | 0.86 | MAP3K12 (0.36) | IRAK4PRKD1PRKD2MAPTGSK3B | |
| SCHEMBL19736178 | 0.85 | CNR2 (0.37) | IRAK4NAMPTMAPTGSK3BACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CBLB 4475/4885IRAK4 2915/4885HPGDS 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.